Chemomab Therapeutics (CMMB) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CMMB Hot Sheet
Join SI Premium – FREE
Chemomab Therapeutics (NASDAQ: CMMB) reported Q2 EPS of ($0.01), $0.09 better than the analyst estimate of ($0.10).
For earnings history and earnings-related data on Chemomab Therapeutics (CMMB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chime Financial, Inc. (CHYM) Tops Q3 EPS by 13c ; Offers Guidance
- Cognex Corp (CGNX) Tops Q3 EPS by 1c, Misses on Revenue; Offers FY26 Guidance
- Cooper-standard Holdings (CPS) Reports Q3 Loss of $0.11, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
